Chemical producer DuPont has provided an undisclosed amount of funding to US-based genome editing technology developer Caribou Biosciences which will form part of the $11m in series A funding Caribou raised in April this year. DuPont made the equity investment as part of a collaboration and licensing agreement, and joins series A investors including pharmaceutical company Novartis, Fidelity Biosciences, Mission Bay Capital and 5 Prime Ventures.
Singapore-based online financial advice service MoneySmart has raised S$2.8m ($2m) in a series…
